This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September 

DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.  

New potential therapy for schizophrenia patients 

Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022. 

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom. 

Data shows promise for patients with asthma and comorbid nasal polyps 

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps. 

Exscientia and Gates Foundation’s antiviral therapeutics 

Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics.   

New mass spectrometry portfolio to advance quantitative analysis 

According to Thermo Fisher Scientific, lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can use its new mass specrometry (MS) portfolio and chromatography solutions to accelerate throughput and improve sensitivity to meet rapidly changing regulatory requirements and the fast responses needed to tackle emerging human and environmental health risks.   

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free